<DOC>
	<DOCNO>NCT02729467</DOCNO>
	<brief_summary>The purpose study assess effect itraconazole , strong cytochrome P ( CYP ) 3A4 p-glycoprotein ( PgP ) inhibitor , rifampicin , CYP3A4 , uridine 5'-diphospho-glucuronosyltransferase ( UGT ) , PgP inducer , inhibitor organic anion-transporting polypeptide ( OATP ) , single-dose pharmacokinetics ( PK ) JNJ-53718678 healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Effects Itraconazole Rifampicin Single-Dose Pharmacokinetics JNJ-53718678 Healthy Adults</brief_title>
	<detailed_description>This single-center , open-label , fixed sequence , Phase 1 study healthy adult participant study effect itraconazole rifampicin pharmacokinetics , safety , tolerability single dose JNJ-53718678 . This study conduct 2 separate panel , 14 participant Panel 1 16 participant Panel 2 . The study consist follow phase : Screening ( 28 day ) , Treatment phase ( 11 day ) Follow-up ( 10 14 day last study drug intake ) . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Participants assess safety tolerability throughout study .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Female participant must negative serum beta human chorionic gonadotropin ( beta hCG ) pregnancy test Screening At Screening , female participant must nonchildbearing potential Participant must Body Mass Index ( BMI ; weight kilogram ( kg ) divide square height meter ) 18.0 30.0 kilogram per meter square ( kg/m2 ) , extremes include Participant must blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mm Hg diastolic Participants must healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination ( include height body weight measurement skin examination ) , medical history , vital sign , result blood biochemistry , blood coagulation , hematology test , urinalysis perform Screening Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic insufficiency , renal dysfunction , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Participants abnormal value alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ( great [ &gt; ] 1.00 * upper limit laboratory normal range [ ULN ] ) Participants lack good/reasonable venous access Participants past history heart arrhythmia ( extrasystoli , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( example hypokalemia , family history long QT Syndrome ) Participants history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-53718678</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>